Cross-Market Price Comparison
| Other Listed Market | Shanghai (SSE) — 昭衍新药 |
|---|---|
| Other Market Stock Code | 603127 |
| H-Share Offer Price | HK$ 151.00 |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | Joinn |
|---|---|
| Stock Code | 06127 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 本公司是一家專注於藥物非臨床安全性評價的領先合同研究組織,正擴展以提供涵蓋藥物研發服務鏈上藥物發現、臨床前和臨床試驗階段的綜合服務,主要包括非臨床研究、臨床試驗及相關服務以及實驗模型業務。 |
| Listing Date | 2021-02-26 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京經濟技術開發區榮京東街甲5號 |
| Business Address (Hong Kong) | 香港皇后大道東183號合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | joinn-lab.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | Yes (A股) |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 151.00 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 100 shares |
| Entry Threshold | HK$ 15,100 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2021-02-16 to 2021-02-19 |
| Global Offering Shares | 43,324,800 shares |
| HK Public Offer Shares (Initial) | 3,899,300 shares (9.0%) |
| Public Offer Lots (Initial) | 38,993lots (Pool A19,496lots,Pool B19,497lots) |
| International Placing Shares (Initial) | 39,425,500 shares (91.0%) |
| Offer Ratio | ~9.0% |
| Total Shares Post-IPO | 270,779,529 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 31.8% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 6,542,044,800 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 100 | HK$ 15,100 |
| 2 lots | 200 | HK$ 30,200 |
| 3 lots | 300 | HK$ 45,300 |
| 4 lots | 400 | HK$ 60,400 |
| 5 lots | 500 | HK$ 75,500 |
| 6 lots | 600 | HK$ 90,600 |
| 7 lots | 700 | HK$ 105,700 |
| 8 lots | 800 | HK$ 120,800 |
| 9 lots | 900 | HK$ 135,900 |
| 10 lots | 1,000 | HK$ 151,000 |
| 15 lots | 1,500 | HK$ 226,500 |
| 20 lots | 2,000 | HK$ 302,000 |
| 25 lots | 2,500 | HK$ 377,500 |
| 30 lots | 3,000 | HK$ 453,000 |
| 35 lots | 3,500 | HK$ 528,500 |
| 40 lots | 4,000 | HK$ 604,000 |
| 45 lots | 4,500 | HK$ 679,500 |
| 50 lots | 5,000 | HK$ 755,000 |
| 60 lots | 6,000 | HK$ 906,000 |
| 70 lots | 7,000 | HK$ 1,057,000 |
| 80 lots | 8,000 | HK$ 1,208,000 |
| 90 lots | 9,000 | HK$ 1,359,000 |
| 100 lots | 10,000 | HK$ 1,510,000 |
| 200 lots | 20,000 | HK$ 3,020,000 |
| 300 lots | 30,000 | HK$ 4,530,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 400 lots | 40,000 | HK$ 6,040,000 |
| 500 lots | 50,000 | HK$ 7,550,000 |
| 600 lots | 60,000 | HK$ 9,060,000 |
| 700 lots | 70,000 | HK$ 10,570,000 |
| 800 lots | 80,000 | HK$ 12,080,000 |
| 900 lots | 90,000 | HK$ 13,590,000 |
| 1,000 lots | 100,000 | HK$ 15,100,000 |
| 2,000 lots | 200,000 | HK$ 30,200,000 |
| 3,000 lots | 300,000 | HK$ 45,300,000 |
| 4,000 lots | 400,000 | HK$ 60,400,000 |
| 5,000 lots | 500,000 | HK$ 75,500,000 |
| 6,000 lots | 600,000 | HK$ 90,600,000 |
| 7,000 lots | 700,000 | HK$ 105,700,000 |
| 8,000 lots | 800,000 | HK$ 120,800,000 |
| 9,000 lots | 900,000 | HK$ 135,900,000 |
| 10,000 lots | 1,000,000 | HK$ 151,000,000 |
| 15,000 lots | 1,500,000 | HK$ 226,500,000 |
| 19,496 lots | 1,949,600 | HK$ 294,389,600 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 2.65B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 40,887,708,879 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 6,542,044,800 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣187.7百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2017 | 2018 | 2019 |
|---|---|---|---|
| Profit before tax | 97,419 | 124,794 | 216,759 |
| Profit for the year | 79,917 | 105,471 | 187,677 |
| Profit attributable to owners | 79,917 | 105,320 | 187,838 |
Balance Sheet
| Item | 2017 | 2018 | 2019 | 2020-09 |
|---|---|---|---|---|
| Cash and cash equivalents | 254,617 | 148,693 | 176,958 | |
| Trade and bills receivables | 40,543 | 56,476 | 97,388 | |
| Inventories | 10,338 | 12,969 | 49,555 | |
| Total current assets | 619,927 | 714,502 | 715,919 | |
| Total assets | 974,126 | 1,176,976 | 1,570,141 | |
| Total current liabilities | 323,106 | 424,506 | 554,051 | |
| Total liabilities | 397,571 | 509,556 | 720,196 | |
| Total equity | 576,555 | 667,420 | 849,945 | |
| Equity attributable to owners | 576,203 | 667,219 | 849,200 | |
| Interest-bearing borrowings | 0 | 0 | 22,323 | 26,227 |
Cash Flow Statement
| Item | 2017 | 2018 | 2019 | 2020-09 |
|---|---|---|---|---|
| Net cash from operating activities | 118,320 | 160,824 | 148,939 | |
| Net cash from investing activities | -220,530 | -252,045 | -103,723 | |
| Depreciation of PP&E | 23,519 | 27,310 | 42,277 | 50,798 |
| Amortisation of intangible assets | 550 | 853 | 2,375 | 8,295 |
| Purchase of PP&E | -23,163 | -128,038 | -120,838 | -121,332 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 138.0 |
|---|---|
| First Day Open | HK$ 148.0 |
| First Day Change | -8.61% |
| First Day Volume | 11667400.0 |
| First Day Turnover | 1675200000.0 |
| Use of Proceeds | 1、16.0%或1,005.8百萬港元將用于進一步擴大我們于蘇州的設施網絡乃為我們的未來增長提供必要的支持;
2、10.0%或628.6百萬港元將用于增強我們的美國業務以迎合客戶對Biomere所提供服務日益增長的需求;
3、39.0%或2,451.6百萬港元將用于進一步擴大我們于中國的設施網絡及服務能力;
4、5.0%或314.3百萬港元將用于拓展及深化我們的綜合合同研究組織服務;
5、20%或1,257.2百萬港元將用于進一步實施我們拓寬藥物研發價值鏈上的綜合服務范圍并拓展海外布局的策略;
6、10%或628.6百萬港元將用于營運資金及一般企業用途。 |
Underwriting Syndicate
Sole Sponsor (1)
中信证券(香港)有限公司 CE AAK249
Overall Coordinators (3)
Joint Bookrunners (9)
Joint Lead Managers (9)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Carmignac Funds | 155,046,800 HKD | — | 2.40% | — | 6 months | 2021-08-26 |
| 2 | CPE Greater China Enterprises Growth Fund | 271,347,000 HKD | — | 4.10% | — | 6 months | 2021-08-26 |
| 3 | CRF Investment Holdings Company Limited | 232,585,300 HKD | — | 3.60% | — | 6 months | 2021-08-26 |
| 4 | Janchor Partners Pan-Asian Master Fund | 232,585,300 HKD | — | 3.60% | — | 6 months | 2021-08-26 |
| 5 | Lake Bleu Prime Healthcare Master Fund Limited | 294,601,000 HKD | — | 4.50% | — | 6 months | 2021-08-26 |
| 6 | Octagon Capital Advisors LP | 77,523,400 HKD | — | 1.20% | — | 6 months | 2021-08-26 |
| 7 | OrbiMed Funds | 271,347,000 HKD | — | 4.10% | — | 6 months | 2021-08-26 |
| 8 | SCC Growth VI Holdco F, Ltd. | 232,585,300 HKD | — | 3.60% | — | 6 months | 2021-08-26 |
| 9 | The Valliance Fund | 38,761,700 HKD | — | 0.60% | — | 6 months | 2021-08-26 |
| 10 | 中国国有企业结构调整基金股份有限公司 | 271,347,000 HKD | — | 4.10% | — | 6 months | 2021-08-26 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 馮宇霞 | — |
| Company Secretary | 高大鵬、吳卓明 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 馮宇霞女士及周先生(配偶)為一組控股股東,截至最後實際可行日期合共持有本公司已發行股份約43.37%,其中馮女士直接持有28.17%,周先生直接持有15.20%。 |
|---|




